Open AccessMonotherapy with either dolutegravir or raltegravir fails to durably suppress HIV viraemia in humanized mice
Author(s) -
Alonso Heredia,
Said Hassounah,
Sandra Medina-Moreno,
Juan Carlos Zapata,
Nhut Le,
Ying-Shan Han,
James S. Foulke,
Charles C. Davis,
Joseph Bryant,
Robert Redfield,
Mark A. Wainberg
Publication year - 2017
Publication title -
journal of antimicrobial chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.124
H-Index - 194
eISSN - 1460-2091
pISSN - 0305-7453
DOI - 10.1093/jac/dkx195
Subject(s) - dolutegravir , raltegravir , integrase inhibitor , virology , viral load , pharmacology , viral replication , integrase , biology , medicine , virus , human immunodeficiency virus (hiv) , antiretroviral therapy
To compare the effectiveness of HIV integrase inhibitor monotherapy between raltegravir and dolutegravir as an approach to simplify therapy.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom